Mitochondria-Targeting Peptide Delivers Chemo Drug to Stop Breast Cancer Spread in Mice
A hybrid peptide targeting mitochondria delivered doxorubicin directly to breast cancer cell powerhouses, eliminating lung metastasis in mice by shutting down invasion pathways.
Quick Facts
What This Study Found
P-D-R8MTS completely prevented lung metastasis in 4T1-bearing mice while inhibiting tumor growth, by delivering doxorubicin to mitochondria and downregulating MMP-2, VEGF, and TGF-β.
Key Numbers
R8+ALD5MTS hybrid peptide; HPMA-DOX carrier; pH-responsive release; no lung metastasis; downregulated MMP-2, VEGF, TGF-β
How They Did This
Polymer-peptide-drug conjugate design; in vitro testing on 4T1 and MDA-MB-231 breast cancer cells (proliferation, migration, invasion assays); in vivo 4T1 mouse tumor model with lung metastasis assessment; protein analysis of MMP-2, VEGF, TGF-β.
Why This Research Matters
Metastasis — not the primary tumor — kills most cancer patients. A delivery system that specifically targets cancer cell mitochondria to block both tumor growth and spread addresses the most lethal aspect of breast cancer.
The Bigger Picture
Mitochondria-targeted cancer therapy is an emerging strategy. By attacking the organelle that powers both cancer cell survival and invasion machinery, this approach tackles metastasis at its metabolic root.
What This Study Doesn't Tell Us
Mouse model with unspecified group sizes; only breast cancer tested; long-term toxicity of the polymer-peptide system not fully characterized; doxorubicin cardiotoxicity concerns remain.
Questions This Raises
- ?Does mitochondrial targeting reduce doxorubicin's well-known heart toxicity?
- ?Would this platform work against other metastatic cancers (pancreatic, colorectal)?
- ?Can the zero-metastasis result be replicated in larger animal models?
Trust & Context
- Key Stat:
- Zero lung metastases P-D-R8MTS completely prevented lung metastatic nodules in 4T1 breast cancer mice
- Evidence Grade:
- Moderate — compelling in vivo anti-metastasis results with mechanistic in vitro data, but unspecified group sizes and single cancer type.
- Study Age:
- Published in 2020; mitochondria-targeted cancer therapies are in active development.
- Original Title:
- A novel mitochondrial targeted hybrid peptide modified HPMA copolymers for breast cancer metastasis suppression.
- Published In:
- Journal of controlled release : official journal of the Controlled Release Society, 325, 38-51 (2020)
- Authors:
- Li, Qiuyi, Yang, Jiatao, Chen, Cheng(3), Lin, Xi, Zhou, Minglu, Zhou, Zhou, Huang, Yuan
- Database ID:
- RPEP-04948
Evidence Hierarchy
Frequently Asked Questions
Why target mitochondria in cancer cells?
Mitochondria power cancer cell invasion and survival. Destroying them shuts down both the energy supply for metastasis and triggers cell death.
What is R8MTS?
A hybrid peptide combining octaarginine (R8, which penetrates cell membranes) with a mitochondrial targeting sequence (MTS), acting as a molecular GPS to deliver drugs directly to mitochondria.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04948APA
Li, Qiuyi; Yang, Jiatao; Chen, Cheng; Lin, Xi; Zhou, Minglu; Zhou, Zhou; Huang, Yuan. (2020). A novel mitochondrial targeted hybrid peptide modified HPMA copolymers for breast cancer metastasis suppression.. Journal of controlled release : official journal of the Controlled Release Society, 325, 38-51. https://doi.org/10.1016/j.jconrel.2020.06.010
MLA
Li, Qiuyi, et al. "A novel mitochondrial targeted hybrid peptide modified HPMA copolymers for breast cancer metastasis suppression.." Journal of controlled release : official journal of the Controlled Release Society, 2020. https://doi.org/10.1016/j.jconrel.2020.06.010
RethinkPeptides
RethinkPeptides Research Database. "A novel mitochondrial targeted hybrid peptide modified HPMA ..." RPEP-04948. Retrieved from https://rethinkpeptides.com/research/li-2020-a-novel-mitochondrial-targeted
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.